STOCK TITAN

ACADIA Pharmaceuticals Inc. - $ACAD STOCK NEWS

Welcome to our dedicated page for ACADIA Pharmaceuticals news (Ticker: $ACAD), a resource for investors and traders seeking the latest updates and insights on ACADIA Pharmaceuticals stock.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. Established with a commitment to scientific excellence and leadership in CNS research, Acadia's proprietary drug discovery platform has enabled the creation of a robust portfolio targeting conditions such as Parkinson's disease psychosis, Alzheimer's disease psychosis, Rett syndrome, and schizophrenia.

Acadia's pivotal achievements include the development and commercialization of NUPLAZID, the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE, the first and only FDA-approved drug for the treatment of Rett syndrome. The company's clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.

Situated in San Diego, one of the largest biotechnology hubs in the United States, Acadia benefits from proximity to over 400 companies and renowned research institutions like the Salk Institute for Biological Studies. This strategic location supports Acadia's mission to bring groundbreaking therapies to patients in need.

Financially, Acadia has shown significant growth, with total revenues reaching $205.8 million for the first quarter of 2024, reflecting a 74% year-over-year increase, largely due to the strong market performance of NUPLAZID and the addition of DAYBUE. The company continues to invest in its pipeline and commercial operations, maintaining a solid cash position with $470.5 million in cash, cash equivalents, and investment securities as of March 31, 2024.

Recent highlights include participation in major healthcare conferences, strategic appointments to enhance leadership in research and development, and ongoing efforts to expand the reach of DAYBUE beyond the U.S. market. Acadia’s unwavering dedication to advancing neuroscience and improving patient outcomes underscores its long-term growth potential and commitment to innovation in the biopharmaceutical landscape.

Rhea-AI Summary

Acadia Pharmaceuticals announced that on May 15, 2024, its Compensation Committee granted inducement awards under the 2023 Inducement Plan. The awards include non-qualified stock options to purchase 57,252 shares of common stock and 33,675 restricted stock units (RSUs) to twenty-two new employees. The stock options have an exercise price of $15.12 per share, Acadia's closing trading price on the grant date, and will vest over four years. The RSUs will also vest over four years, with specific vesting schedules. These awards were granted as an inducement material in line with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
-
Rhea-AI Summary

Acadia Pharmaceuticals has launched a 10-part documentary series, 'Magnolia’s Guide to Adventuring,' featuring the adapted adventures of families dealing with Rett syndrome. Created by award-winning TV producer AJ Tesler and his wife Jenny, the series stars their 13-year-old daughter, Magnolia. The series aims to raise awareness and redefine perceptions of Rett syndrome by showcasing activities like skiing, ice skating, and horseback riding. Episodes will be available on the Rett Revealed website. The series underscores the resilience and capabilities of those living with Rett syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
-
Rhea-AI Summary

Acadia Pharmaceuticals (ACAD) announced its participation in three upcoming investor conferences in May 2024, aiming to engage with the investment community. The company will host fireside chats at each conference, providing insights into its innovative work in neuroscience. Acadia has a strong track record with FDA-approved drugs for Parkinson's disease psychosis and Rett syndrome, while also focusing on developing treatments for Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
conferences
Rhea-AI Summary

Acadia Pharmaceuticals reported strong financial results for the first quarter of 2024, with net product sales reaching $205.8 million, a 74% year-over-year revenue growth. The increase was primarily driven by the addition of DAYBUE for Rett syndrome treatment and growth in NUPLAZID market share for Parkinson's disease psychosis. The company is focusing on expanding DAYBUE globally, advancing late-stage trials, and supporting its pipeline and business development opportunities. Acadia also presented positive clinical trial results and appointed a new executive to lead Research and Development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.21%
Tags
-
Rhea-AI Summary

Acadia Pharmaceuticals announced the winners of the first Rett Sibling Scholarship, awarding 10 academic scholarships to siblings of Rett syndrome patients. Each recipient will receive $5,000 for higher education. The program aims to support siblings' academic goals and recognize their contributions. Recipients from various states plan to study psychology, finance, and medicine. The scholarship is independently administered by ISTS. Acadia's commitment to the Rett syndrome community is highlighted through this initiative.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
none
-
Rhea-AI Summary
Acadia Pharmaceuticals (Nasdaq: ACAD) will announce its first quarter financial results on May 8, 2024. The company will host a conference call and webcast to discuss financial results and operations. The call will be available on Acadia's website and archived until June 7, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
Rhea-AI Summary
Acadia Pharmaceuticals has announced that Health Canada has accepted the New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, granting Priority Review. The submission is supported by positive Phase 3 study results, showing significant improvements in patients. If approved, trofinetide will be the first treatment option for Rett syndrome in Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
-
Rhea-AI Summary
Acadia Pharmaceuticals announced the grant of inducement awards to new employees under the 2023 Inducement Plan. The awards include non-qualified stock options and restricted stock units. Each stock option has an exercise price of $17.73 per share and will vest over four years, while the RSUs will also vest over four years. The awards were granted as inducements material to the new employees' employment, following Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
-
Rhea-AI Summary
Acadia Pharmaceuticals presents new DAYBUE™ (trofinetide) clinical data at the 2024 American Academy of Neurology (AAN) Annual Meeting, showcasing outcomes from the DAFFODIL™ study and caregiver interviews in Rett syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) appoints Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson brings extensive experience in drug research and development, particularly in rare diseases and central nervous system disorders. Her leadership will drive Acadia's growth and pipeline expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
management

FAQ

What does Acadia Pharmaceuticals Inc. specialize in?

Acadia Pharmaceuticals Inc. specializes in developing and commercializing innovative medicines for central nervous system (CNS) disorders.

Where is Acadia Pharmaceuticals headquartered?

Acadia Pharmaceuticals is headquartered in San Diego, California.

What are some of Acadia's key products?

Key products include NUPLAZID, for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE, for the treatment of Rett syndrome.

What recent financial performance did Acadia report?

For the first quarter of 2024, Acadia reported total revenues of $205.8 million, marking a 74% increase year over year.

What are Acadia's current research focuses?

Acadia's research focuses include the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis, and other neuropsychiatric symptoms in CNS disorders.

What recent achievements has Acadia Pharmaceuticals announced?

Recent achievements include strategic leadership appointments, participation in major healthcare conferences, and advancements in their clinical-stage development efforts.

How does Acadia support the Rett syndrome community?

Acadia supports the Rett syndrome community through initiatives like the Rett Sibling Scholarship program and creating awareness with projects like Magnolia’s Guide to Adventuring.

What is the significance of Acadia's location in San Diego?

San Diego is one of the largest biotechnology clusters in the U.S., providing Acadia access to a vibrant ecosystem of over 400 companies and prestigious research institutions.

How has Acadia's product portfolio grown recently?

Acadia's portfolio has grown with the addition of DAYBUE, enhancing their market presence and addressing unmet medical needs in CNS disorders.

What is Acadia’s approach to drug discovery?

Acadia’s proprietary drug discovery platform focuses on internal discoveries, innovative therapeutic approaches, and addressing large unmet needs in CNS disorders.

ACADIA Pharmaceuticals Inc.

Nasdaq:ACAD

ACAD Rankings

ACAD Stock Data

2.46B
109.87M
0.49%
99.56%
6.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO